# Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States

> **NCT07342309** · — · ACTIVE_NOT_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 7933 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07342309
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 7933 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07342309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07342309, "Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07342309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*